Indication
HER2/Neu Negative
30 clinical trials
34 products
23 drugs
Clinical trial
Phase Ib Study of BYL719 (Alpelisib) in Combination With Androgen Receptor Inhibitor (Enzalutamide) in Patients With Androgen Receptor (AR)-Positive and PTEN Positive Metastatic Breast CancerStatus: Completed, Estimated PCD: 2023-12-31
Drug
AlpelisibProduct
EnzalutamideClinical trial
A Phase II Multi-Institutional Study of Concurrent Radiotherapy, Palbociclib, and Hormone Therapy for Treatment of Bone Metastasis in Breast Cancer PatientsStatus: Completed, Estimated PCD: 2022-10-13
Product
AnastrozoleProduct
ExemestaneProduct
FulvestrantProduct
LetrozoleProduct
PalbociclibClinical trial
A Phase II Study of Neoadjuvant Chemotherapy With and Without Trastuzumab in Patients With Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-05-01
Drug
cyclophosphamideProduct
DoxorubicinDrug
TiragolumabDrug
TamoxifenDrug
TrastuzumabClinical trial
MK-3475 (Pembrolizumab) in Combination With an Anthracycline or Anti-estrogen Therapy in Patients With Triple Negative and Hormone Receptor Positive (HR+ HER2-) Metastatic Breast CancerStatus: Completed, Estimated PCD: 2022-04-01
Product
PembrolizumabClinical trial
T-Cell Immune Checkpoint Inhibition Plus Hypomethylation for Locally Advanced HER2-Negative Breast Cancer - A Phase 2 Neoadjuvant Window Trial of Pembrolizumab and Decitabine Followed by Standard Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2022-08-04
Product
CyclophosphamideProduct
PaclitaxelProduct
CarboplatinClinical trial
Phase I Clinical Trial Assessing the Combination of Chemokine Modulation With Neoadjuvant Chemotherapy in Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2022-05-24
Drug
CelecoxibProduct
DecitabineDrug
RintatolimodClinical trial
A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel With or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2026-10-31
Clinical trial
A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients With Hormone Receptor-Positive Advanced Breast CancerStatus: Active (not recruiting), Estimated PCD: 2020-05-05
Product
EntinostatDrug
LHRH agonistProduct
GoserelinClinical trial
A Pilot Pre-Surgical Study Evaluating Anti-PD-L1 Antibody (Durvalumab [MEDI4736]) Plus Anti-CTLA-4 Antibody (Tremelimumab) in Patients With Hormone Receptor Positive, HER2 Negative Breast CancerStatus: Completed, Estimated PCD: 2019-01-31
Drug
AN0025Product
TremelimumabClinical trial
Overcoming PARP Inhibitor Resistance in BRCA Germline Mutation Positive Advanced Breast CancerStatus: Recruiting, Estimated PCD: 2025-03-31
Product
CediranibDrug
CeralasertibProduct
OlaparibDrug
doxorubicinClinical trial
A Randomized Phase II Study of Neoadjuvant Carboplatin/Paclitaxel (CT) Versus Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen for Newly Diagnosed Primary Triple-Negative Inflammatory Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-10-31
Product
PanitumumabClinical trial
Randomized Phase II Trial to Evaluate Alisertib Alone or Combined With Fulvestrant for Women With Advanced, Endocrine-Resistant Breast CancerStatus: Active (not recruiting), Estimated PCD: 2022-01-10
Product
AlisertibClinical trial
A Phase II Study of Anti-PD-1 (MK-3475) Therapy in Patients With Metastatic Inflammatory Breast Cancer (IBC) or Non-IBC Triple Negative Breast Cancer (TNBC) Who Have Achieved Clinical Response or Stable Disease to Prior ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2028-12-31
Drug
mFOLFOX6Clinical trial
A Randomized Phase III Trial of Eribulin Compared to Standard Weekly Paclitaxel as First- or Second-Line Therapy for Locally Recurrent or Metastatic Breast CancerStatus: , Estimated PCD: 2021-02-11
Product
EribulinDrug
AlpelisibClinical trial
A Phase Ib Trial of LY2157299 (TGFβR1 Kinase Inhibitor) With Paclitaxel in Patients With Triple Negative Metastatic Breast CancerStatus: Completed, Estimated PCD: 2021-04-01
Product
GalunisertibClinical trial
Multimodality Breast Imaging for the Assessment of Tumor Response to Neoadjuvant Chemotherapy in Triple Negative Breast Cancer PatientsStatus: Active (not recruiting), Estimated PCD: 2026-04-30
Product
Technetium Tc-99m SestamibiClinical trial
A Randomized Phase III Post-operative Trial of Platinum Based Chemotherapy vs. Capecitabine in Patients With Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant ChemotherapyStatus: Active (not recruiting), Estimated PCD: 2021-04-07
Drug
UTD1Drug
CisplatinClinical trial
A Phase 1 Study of Ipilumumab, Nivolumab and Talimogene Laherparepvec Preoperative Treatment of Localized Breast Cancer-deletedStatus: Terminated, Estimated PCD: 2023-05-17
Drug
LurbinectedinDrug
T-VECProduct
Talimogene LaherparepvecClinical trial
A Phase 1b Study of Talimogene Laherparepvec (T-VEC) in Combination With Chemotherapy or Endocrine Therapy in Patients With Metastatic, Unresectable, or Locoregionally Recurrent HER2-negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Drug
TucidinostatClinical trial
Phase II Trial of Neoadjuvant Chemotherapy With Carboplatin and NAB-Paclitaxel in Patients With Locally Advanced and Inflammatory Triple Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2019-01-11
Drug
carboplatinDrug
AbraxaneClinical trial
A Phase II Randomized Study of Ixabepilone vs. Observation in Patients With Significant Residual Disease After Neoadjuvant Systemic Therapy for HER2/Neu-Negative Breast CancerStatus: Active (not recruiting), Estimated PCD: 2024-12-31
Product
IxabepiloneProduct
Nab paclitaxelDrug
GemcitabineClinical trial
Pilot Open Label Clinical Trial Evaluating the Safety and Efficacy of Chemokine Modulation to Enhance the Effectiveness of Pembrolizumab in Patients With Metastatic Triple Negative Breast CancerStatus: Completed, Estimated PCD: 2020-09-02
Clinical trial
[18F] Fluoroestradiol (FES) PET as a Predictive Measure for Endocrine Therapy in Patients With Newly Diagnosed Metastatic Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-04
Clinical trial
Phase I Trial of Intratumoral Administration of a NIS-Expressing Derivative Manufactured From a Genetically Engineered Strain of Measles Virus in Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck or Metastatic Breast CancerStatus: Completed, Estimated PCD: 2019-09-18
Clinical trial
Atorvastatin in Triple-Negative Breast Cancer (TNBC) Patients Who Did Not Achieve a Pathologic Complete Response (pCR) After Receiving Neoadjuvant Chemotherapy, a Multicenter Pilot StudyStatus: Completed, Estimated PCD: 2023-10-19
Drug
AtorvastatinClinical trial
A Phase 2 Clinical Trial of the Combination of Pembrolizumab and Selective Androgen Receptor Modulator (SARM) GTX-024 in Patients With Metastatic Androgen Receptor (AR) Positive Triple Negative Breast Cancer (TNBC)Status: Completed, Estimated PCD: 2020-10-28
Product
EnobosarmClinical trial
Phase II Trial of Primary Endocrine Therapy With Combination of Fulvestrant or an Aromatase Inhibitor and Palbociclib in Elderly Patients With Hormone Responsive Breast Cancer Who Have Inoperable Tumor Or Operable Tumor But Cannot Undergo Surgery Due to Frailty Or Who Refuse SurgeryStatus: Recruiting, Estimated PCD: 2023-12-31
Clinical trial
A Phase II Clinical Trial of the PARP Inhibitor Talazoparib in BRCA1 and BRCA2 Wild Type Patients With Advanced Triple Negative Breast Cancer and Homologous Recombination Deficiency or Advanced HER2 Negative Breast Cancer or Other Solid Tumors With a Mutation in Homologous Recombination Pathway GenesStatus: Completed, Estimated PCD: 2019-12-23
Product
TalazoparibProduct
Aromatase InhibitorsClinical trial
A Phase 1b Study of ALRN-6924 in Combination With Paclitaxel in Wild-Type TP53 Advanced or Metastatic Solid Tumors Including Estrogen-Receptor Positive Breast CancerStatus: Active (not recruiting), Estimated PCD: 2025-04-30
Product
ALRN-6924Clinical trial
A Phase Ib Study of the Oral PARP Inhibitor Olaparib With the Oral mTORC1/2 Inhibitor AZD2014 or the Oral AKT Inhibitor AZD5363 for Recurrent Endometrial, Triple Negative Breast, and Ovarian, Primary Peritoneal, or Fallopian Tube CancerStatus: Active (not recruiting), Estimated PCD: 2025-12-30
Product
CapivasertibDrug
olaparibProduct
Vistusertib